/
AVBP
$34.74+$0.37 (+1.08%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.6B
47M shares
52-week range
$16.10 – $35.83
94% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.58%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$14.74
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — |
| R&D | $6.4M | $30.4M | $64.9M | $79.0M | $153.4M |
| Operating income | −$8.7M | −$36.9M | −$74.6M | −$94.3M | −$177.5M |
| EBITDA | −$51.6M | $0 | −$69.3M | −$80.5M | −$166.3M |
| Net income | −$51.6M | −$36.9M | −$69.3M | −$80.5M | −$166.3M |
| Net margin | — | — | — | — | — |
| EPS (diluted) | -40.44 | -1.10 | -2.17 | -2.56 | -4.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $125000 | $-4.05 | $-4.18–$-3.76 | 9 |
| 2027 | $44M | $-3.44 | $-3.62–$-3.26 | 6 |
| 2028 | $154M | $-1.41 | $-2.44–$1.10 | 6 |
| 2029 | $318M | $1.14 | $0.54–$1.70 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.05
Price
$34.74
Implied downside
-97%
Peer comparison
ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
www.arrivent.com- Employees
- 77
- IPO / List date
- Jan 26, 2024
- HQ
- NEWTOWN SQUARE, PA
Held by traders on TradeandTell
No one on the platform currently holds AVBP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AVBP as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AVBP yet.
